Designing a natural experiment to evaluate a national health care-community partnership to prevent type 2 diabetes

Preventing Chronic Disease

Volumn 10, Issue 1, 2013, Pages

  Ackermann, Ronald T ^a   Holmes, Ann M ^b   Saha, Chandan ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHILD; CLUSTER ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECONOMICS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH INSURANCE; HEALTH PROMOTION; HUMAN; LIFESTYLE; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORGANIZATION AND MANAGEMENT; PARTICIPATORY RESEARCH; PATIENT EDUCATION; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STANDARD; UNITED STATES; UTILIZATION REVIEW; WEIGHT REDUCTION;

CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CHILD; CLUSTER ANALYSIS; COMMUNITY-BASED PARTICIPATORY RESEARCH; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HEALTH BENEFIT PLANS, EMPLOYEE; HEALTH EXPENDITURES; HEALTH PROMOTION; HUMANS; INDIANA; INSURANCE, HEALTH; LIFE STYLE; PATIENT EDUCATION AS TOPIC; PROGRAM EVALUATION; RISK ASSESSMENT; UNITED STATES; WEIGHT LOSS;

MLCS; MLOWN;

EID: 84873528553     PISSN: 15451151     EISSN: 21665435     Source Type: Journal    
DOI: 10.5888/pcd10.120149     Document Type: Article

References (21)

1. Diabetes statistics. American Diabetes Association; 2011. http://www.diabetes.org/diabetes-statistics.jsp. Accessed May 22, 2011.
2. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003;290(14):1884-90.
3. Narayan KM, Williamson DF. Prevention of type 2 diabetes: risk status, clinic, and community. J Gen Intern Med 2010;25(2):154-7.
4. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403.
5. Ackermann RT, Edelstein S, Narayan KM, Zhang P, Engelgau MM, Herman WH, et al. Changes in health state utilities with changes in body mass in the Diabetes Prevention Program. Obesity (Silver Spring) 2009;17(12):2176 -81.
6. Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005;142(5):323-32.
7. Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 2005;28(4):888-94.
8. Ackermann RT, Marrero DG, Hicks KA, Hoerger TJ, Sorensen S, Zhang P, et al. An evaluation of cost sharing to finance a diet and physical activity intervention to prevent diabetes. Diabetes Care 2006;29(6):1237-41.
9. Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS. Diabetes Care 2012;35(4):723- 30.
10. Garfield SA, Malozowski S, Chin MH, Venkat Narayan KM, Glasgow RE, Green LW, et al. Considerations for diabetes translational research in real-world settings. Diabetes Care 2003;26(9):2670-4.
11. Ackermann RT, Finch EA, Brizendine E, Zhou H, Marrero DG. Translating the Diabetes Prevention Program into the community. The DEPLOY Pilot Study. Am J Prev Med 2008;35(4):357-63.
12. Ackermann RT, Marrero DG. Adapting the Diabetes Prevention Program lifestyle intervention for delivery in the community: the YMCA model. Diabetes Educ 2007;33(1):69, 74-5, 77-8.
13. Ali MK, Echouffo-Tcheugui J, Williamson DF. How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program? Health Aff (Millwood) 2012;31(1):67-75.
14. Schmittdiel JA, Uratsu CS, Karter AJ, Heisler M, Subramanian U, Mangione CM, et al. Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med 2008;23(5):588-94.
15. Bradlow ET. Encouragement designs: an approach to self-selected samples in an experimental design. Mark Lett 1998;9(4):383-91.
16. Hirano K, Imbens GW, Rubin DB, Zhou XH. Assessing the effect of an influenza vaccine in an encouragement design. Biostatistics 2000;1(1):69-88.
17. Brown CH, Wyman PA, Guo J, Peña J. Dynamic wait-listed designs for randomized trials: new designs for prevention of youth suicide. Clin Trials 2006;3(3):259-71.
18. Zhou XH, Li SM. ITT analysis of randomized encouragement design studies with missing data. Stat Med 2006;25 (16):2737-61.
19. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. J Am Stat Assoc 1996;91(434):444-55.
20. Keogh-Brown MR, Bachmann MO, Shepstone L, Hewitt C, Howe A, Ramsay CR, et al. Contamination in trials of educational interventions. Health Technol Assess 2007;11(43):iii, ix-107.
21. Sussman JB, Hayward RA. An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. BMJ 2010;340:c2073